Nuveen
ARTV icon

Nuveen’s Artiva Biotherapeutics ARTV Stock Holding History

Nuveen’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$184K Buy
+25,804
New +$260K ﹤0.01% 3814
2025
Q2 		– Sell
-47,892
Closed -$144K – 3444
2025
Q1 		$144K Buy
47,892
+29,281
+157% +$158K ﹤0.01% 3171
2024
Q4 		$188K Hold
18,611
– – ﹤0.01% 3216
2024
Q3 		$288K Buy
+18,611
New +$216K ﹤0.01% 3151

Other funds holding ARTV

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

Nuveen's ARTV Position: Q3 2026 in Review

Nuveen opened a new position in Artiva Biotherapeutics (ARTV) in Q3 2026: 25,804 shares worth $184K. The stake represents ﹤0.01% of the portfolio and ranks #3814 among its holdings. This is a return to the name: Nuveen previously reported a position in ARTV as recently as Q1 2025.

Nuveen first reported a position in ARTV in Q3 2024 and has held it in 4 quarters since. The position peaked at $288K in Q3 2024. 34 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

  • Nuveen held 25,804 shares of Artiva Biotherapeutics worth $184K as of Q3 2026.
  • Artiva Biotherapeutics was a new Nuveen position in Q3 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #3814 holding.
  • Nuveen first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 4 quarters since.
  • Nuveen's Artiva Biotherapeutics position peaked at $288K in Q3 2024.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.